Overview
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
Status:
Completed
Completed
Trial end date:
2006-12-01
2006-12-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
This is a placebo-controlled, double-blind study to evaluate the safety and efficacy of two doses of DR-3001 in women with overactive bladder who have symptoms of predominant or pure urge incontinence, urinary urgency and elevated urinary frequencyPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Duramed Research
Criteria
Inclusion Criteria:- Diagnosis of overactive bladder and incontinence for at least 6 months
- Using birth control or menopausal
- Willing to discontinue current medication for overactive bladder
Exclusion Criteria:
- Pregnant or given birth in the last 6 months
- Three or more urinary tract infections a year
- Uncontrolled glaucoma, hypertension, diabetes or myasthenia gravis
- History of bladder cancer, ulcerative colitis or severe constipation
- Any contraindication to vaginal delivery systems